Evercore ISI analyst Umer Raffat maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday. The company’s shares closed ...

The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click ...

The S&P 500 slipped after a strong U.S. inflation report dashed hopes for rate cuts. CVS Health and Gilead Sciences rose on positive earnings, contrasting Nvidia and Amazon's declines. President Trump ...

Investors led by Elon Musk offer $97.4 billion for OpenAI. Sam Altman replies: 'No thank you.' ...

The S&P 500 dipped amid news of higher-than-expected U.S. inflation, dampening hopes for a Federal Reserve rate cut. Despite ...

Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025.

Shares of Gilead Sciences ( GILD 7.46%) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the big ...

The settlement in U.S. v. Gilead could disturb the model of public-private partnership that sustains many of the United ...

US biotech major Gilead Sciences was trading nearly 5% higher in Wednesday’s pre-market trading after presenting its fourth ...

Brent Greetham has been appointed chief financial officer at Surgical Innovations, with effect from 24 February 2025. Chris ...

Operator Good afternoon, everyone, and welcome to Gilead's fourth quarter and full year 2024 earnings conference call. My ...

Gilead Sciences, Inc. ( NASDAQ: GILD) Q4 2024 Earnings Conference Call February 11, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...